Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein.

Nicolas TorresMaría Victoria ReggeFlorencia SecchiariAdrián David FriedrichRaúl Germán SpallanzaniXimena Lucía Raffo IraolagoitiaSol Yanel NúñezJessica Mariel SierraAndrea ZiblatMaría Cecilia SantilliNicolás GilioEvangelina AlmadaConstanza LaucheRomina PardoCarolina Inés DomaicaMercedes Beatriz FuertesKevin Patrick MadaussKenneth W HanceIsrael S GlogerVanesa ZylbermanFernando Alberto GoldbaumNorberto Walter Zwirner

Published in: Journal for immunotherapy of cancer (2020)

Immunization with the chimeric protein BLS-MICA constitutes a useful way to actively induce therapeutic anti-MICA pAb that resulted in a reprogramming of the antitumor immune response towards an antitumoral/proinflammatory phenotype. Hence, the BLS-MICA chimeric protein constitutes a novel antitumor vaccine of potential application in patients with MICA-expressing tumors.

Keyphrases

cell therapy
immune response
protein protein
amino acid
binding protein
dendritic cells
small molecule
toll like receptor
inflammatory response
bone marrow
climate change
wild type